Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of inducement awards to cokey nguyen, its senior vice president, chief scientific officer. the compensation committee of atara's board of directors granted dr
ATRA Ratings Summary
ATRA Quant Ranking